Table 2 Summary of efficacy outcomes at weeks 12 and 24

ADAS-Cog^a

   Evaluable patients

17

6

16

6

   Improvement^b

7 (41%)

1 (17%)

0.369

6 (38%)

1 (17%)

0.616

   Worsening^b

1 (6%)

3 (50%)

0.040

1 (6%)

3 (50%)

0.046

   Mean absolute change

-2.6 ± 3.6

4.2 ± 6.6

0.016

-1.8 ± 6.1

5.8 ± 7.9

0.030

ADCS-ADL^c

   Evaluable patients

16

6

15

6

   Improvement^d

8 (50%)

0 (0%)

0.051

9 (60%)

1 (17%)

0.149

   Worsening^d

5 (31%)

3 (50%)

0.624

4 (27%)

3 (50%)

0.354

   Mean absolute change

6.9 ± 10.9

-4.2 ± 6.9

0.035

5.5 ± 15.8

-1.8 ± 7.0

0.128

MMSE^c

   Evaluable patients

17

7

16

7

   Mean absolute change

0.1 ± 2.5

-2.1 ± 2.5

0.047

-0.1 ± 4.3

-3.3 ± 3.3

0.031

CDR response^e

   Evaluable patients

17

7

0.778*

16

7

0.293*

   Response

2 (12%)

1 (14%)

3 (19%)

1 (14%)

   No change

14 (82%)

5 (71%)

12 (75%)

4 (57%)

   Worsening

1 (6%)

1 (14%)

1 (6%)

2 (29%)

CIBIC-Plus

   Evaluable patients

17

6

0.292*

16

6

0.474*

   Response (1 to 3)

1 (6%)

1 (17%)

2 (13%)

0

   No change (4)

14 (82%)

2 (33%)

12 (75%)

5 (83%)

   Worsening (5 to 7)

2 (12%)

3 (50%)

2 (13%)

1 (17%)